# **Development of an Integrated Sample Amplification Control for Salivary Point-of-Care Pathogen Testing**

4 Navaporn Sritong<sup>1</sup>, Winston Wei Ngo<sup>1</sup>, Karin F. K. Ejendal<sup>1</sup>, Jacqueline C. Linnes<sup>1,2\*</sup>

- 1: Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA
- 2: Department of Public Health, Purdue University, West Lafayette, IN, USA
- \* [jlinnes@purdue.edu,](mailto:jlinnes@purdue.edu) +1-765-409-1012
- 

## **Keywords**

- Reverse transcription Loop-mediated isothermal amplification, SARS-CoV-2, Diagnostic, Lateral flow
- immunoassay, Internal amplification control, Saliva
- 
- **Abstract**

 Background: The COVID-19 pandemic has led to a rise in point-of-care (POC) and home-based tests, but concerns over usability, accuracy, and effectiveness have arisen. The incorporation of internal amplification 16 controls (IACs), essential control for translational POC diagnostics, could mitigate false- negative and false-<br>17 ositive results due to sample matrix interference or inhibition. Although emerging POC nucleic acid positive results due to sample matrix interference or inhibition. Although emerging POC nucleic acid amplification tests (NAATs) for detecting SARS-CoV-2 show impressive analytical sensitivity in the lab, the assessment of clinical accuracy with IACs is often overlooked. In some cases, the IACs were run spatially, complicating assay workflow. Therefore, the multiplex assay for pathogen and IAC is needed.

 Results: We developed a one-pot duplex reverse transcriptase loop-mediated isothermal amplification (RT- LAMP) assay for saliva samples, a non-invasive and simple collected specimen for POC NAATs. The ORF1ab gene of SARS-CoV-2 was used as a target and a human 18S ribosomal RNA in human saliva was employed as an IAC to ensure clinical reliability of the RT-LAMP assay. The optimized assay could detect SARS-CoV-2 viral particles down to 100 copies/μL of saliva within 30 minutes without RNA extraction. The duplex RT-LAMP for SARS-CoV-2 and IAC is successfully amplified in the same reaction without cross-reactivity. The valid results were easily visualized in triple-line lateral flow immunoassay, in which two lines (flow control and IAC lines) represent valid negative results and three lines (flow control, IAC, and test line) represent valid positive results. This duplex assay demonstrated a clinical sensitivity of 95%, specificity of 100%, and accuracy of 96% in 30 clinical saliva samples. 

- Significance: IACs play a crucial role in ensuring user confidence with respect to the accuracy and reliability of at-home and POC molecular diagnostics. We demonstrated the multiplex capability of SARS- COV-2 and human18S ribosomal RNA RT-LAMP without complicating assay design. This generic platform can be extended in a similar manner to include human18S ribosomal RNA IACs into different clinical sample matrices.
- 
- 
- 
- 
- 
- 
- 

### **Introduction**

 Due to the COVID-19 pandemic, there has been a rapid increase in the development and availability of point-of-care (POC) and home-based nucleic acid amplification tests (NAATs) for respiratory infections. However, this has also given rise to user concerns regarding the accuracy and effectiveness of these tests and has raised questions about the future of at-home diagnostics for other infectious diseases [1]. Without the same level of quality control and assurance as laboratory-based tests, sample quality and the way it is collected and handled can lead to challenges with accuracy, reliability, and reproducibility [2].

56 According to the US FDA guidelines for *in vitro* diagnostic devices, internal analytical controls (IACs) are<br>57 among the essential controls mandated for the industry [3]. In the lab, an IAC is commonly run in parallel among the essential controls mandated for the industry [3]. In the lab, an IAC is commonly run in parallel with NAATs in order to rule out a false-negative result [4] and to qualify the sample collection process as well as the integrity of the amplification enzymes and conditions in a presence of complex matrix [5]. An IAC, sometimes referred to as a sample adequacy control, can contain a synthetic target sequence of different length, a non-target sequence, or a housekeeping gene of human cells to ensure sample is adequately collected and prepared. IACs are also crucial in POC diagnostics to ensure accurate and reliable detection, particularly when performed at locations with limited access to laboratory facilities [6]. The inclusion of an IAC in POC diagnostics can help to reduce the risk of false-negative results, which can have serious implications for the management of infectious diseases due to delayed or inadequate treatment, potentially resulting in disease transmission, increased morbidity, and mortality [7].

While many emerging publications on NAATs for SARS-CoV-2 show remarkable analytical sensitivity in

69 the laboratory setting [8], assessing clinical accuracy with IAC is often overlooked. Incorporating an IAC is often overlooked. Incorporating an IAC is often overlooked. Incorporating an IAC is often proceed.

into POC NAATs can present challenges such as requirements of more complex assay design and higher

volume of samples to run the control, which subsequently leads to additional user step. Nevertheless, there

 are some works that have integrated an IAC on their diagnostic assays as shown in Table 1. Reported IACs were performed in separated reactions from tests for the virus, leading additional user steps, increased cost

of reagents, and increased risk of contamination between samples[9–15] . In contrast, a one-pot multiplexed

reaction can streamline the assay workflow, decrease the required sample volume, and mitigate the

likelihood of cross-contamination among reaction zones, leading to enhanced assay efficacy [16]. While

details are not stated, some portable and benchtop commercial SARS-CoV-2 molecular diagnostic tests

 such as ID NOW™ COVID-19 2.0, Visby Medical Respiratory Health Test, Aptitude Metrix™ COVID-79 19 test, and Cue's COVID-19 Diagnostic Test included IAC in their tests as part of result interpretation 80 [17].

 $[17]$ .

 Isothermal amplification reactions, such as reverse transcription loop-mediated isothermal amplification (RT-LAMP) for the detection of SARS-CoV-2 have recently been highlighted due to their key features: rapid detection without the need for sophisticated equipment or specialized training [18], reagent accessibility [19], comparable sensitivity and specificity [20]. With 6 separate primers required, 86 multiplexed RT-LAMP are commonly not considered. However, multiple publications have demonstrated<br>87 that RT-LAMP assays can be multiplexed to detect multiple targets in a single reaction [21–23]. These can that RT-LAMP assays can be multiplexed to detect multiple targets in a single reaction  $[21-23]$ . These can be achieved by including multiple primer sets targeting different regions of the target sequence, as well as incorporating separate probes to differentiate the amplified products.

Choosing an appropriate sample matrix for viral infection diagnosis is essential as it plays a key role in

 obtaining reliable diagnostic results. Saliva has been reported as an alternative to nasopharyngeal specimens for respiratory virustesting including SARS-CoV-2 [24]. Overall, saliva sampling offers several advantages

in terms of simplicity for users. Saliva collection is user-friendly and can be performed without medical

personnel, reducing the burden on healthcare professionals. Due to its non-invasive nature, saliva sampling

is less intimidating, especially for children and older individuals who may have difficulty with nasal swab

 collection [25]. Moreover, the time required for specimen collection and the associated cost of using saliva are significantly lower compared to using nasopharyngeal specimens [26].

99<br>100 Despite being easier to collect, salivary components have been demonstrated to hinder RT-LAMP reactions,

posing similar challenges to those observed with nasal swab samples. As a result, false-negative results due

to assay failure could be observed. To improve clinical accuracy and ease of use and avoiding the drawbacks

 of a parallel reaction, we have developed a one-pot duplex RT-LAMP assay that uses human 18S ribosomal RNA (18S rRNA) as an IAC in human saliva with the ORF1ab gene of SARS-CoV-2 as the target pathogen. 105 Our optimized assay can detect SARS-CoV-2 viral particles as low as 100 copies/ $\mu$ L of saliva within 30

106 minutes. The duplex RT-LAMP for SARS-CoV-2 and IAC can be amplified in one-pot reactions without cross-reactivity, and valid results are easily visualized in triple-line lateral flow immunoassays (LFIAs). cross-reactivity, and valid results are easily visualized in triple-line lateral flow immunoassays (LFIAs).

- The appearance of flow control and IAC lines represent valid negative results, and the flow control, IAC, and test lines represent valid positive results. The duplex RT-LAMP assay was validated directly on clinical
- saliva samples without prior RNA extraction. The IAC developed here meet the FDA guidelines for *In*
- *Vitro* Diagnostic Devices [6] to bring clinically relevant molecular diagnostic into POC settings without
- complicating platform design.
- 

# **2. Materials and methods**

- 
- *2.1 Reagents*

 Reagents for RT-LAMP reactions included WarmStart® Multi-Purpose LAMP/RT-LAMP 2X Master Mix 119 with UDG from NEB (Ipswich, MA), EvaGreen from VWR International (Radnor, PA), ROX from Thermo<br>120 Fisher Scientific (Waltham, MA), and nuclease-free water from Invitrogen (Waltham, MA). Pooled human Fisher Scientific (Waltham, MA), and nuclease-free water from Invitrogen (Waltham, MA). Pooled human saliva used in assay development was purchased from Innovative Research (Novi, MI). BtsYI and Ddel restriction enzymes were purchased from NEB (Ipswich, MA). The viral templates obtained from BEI Resources (Manassas, VA) included Heat inactivated Novel Coronavirus, 2019-nCoV/USA-WA1/2020, NR-52286 (SARS-CoV-2); Middle East Respiratory Syndrome Coronavirus (MERS CoV), EMC/2012, Irradiated Infected Cell Lysate, NR-50549; and SARS Coronavirus (SARS), NR-9547; and purified genomic RNA from dengue virus (DENV) type 1. All primers, including those conjugated to FITC, biotin and DIG, were ordered from Integrated DNA Technologies (Coralville, IA).

*2.2 Singleplex RT-LAMP for SARS-CoV-2 detection*

 The primer set targeting ORF1ab region of SARS-CoV-2 (GenBank: OQ691200.1) was used (Table S1.). The RT-LAMP reactions were carried out by using 2x WarmStart® Multi-Purpose LAMP/RT-LAMP Master Mix in accordance with the New England Biolab standard and 10X Primer Mix containing all 6 LAMP primers (final concentration of 1.6 µM for forward inner primer (FIP) and backward inner primer 135 (BIP), 0.4  $\mu$ M for forward loop primer (LF) and backward loop primer (LB), and 0.2  $\mu$ M for forward outer 136 primer (F3) and backward outer primer (B3). The 5' end of LF and LB were labeled with fluorescein (FITC) or biotin, respectively for LFIA detection. The robustness of primer sets in various saliva percentages (0- or biotin, respectively for LFIA detection. The robustness of primer sets in various saliva percentages (0- 30%) were evaluated to determine volume of saliva sample used in the assay. Various concentrations of SARS-CoV-2 viral particles were spiked into saliva samples at concentrations ranging from 0 to 5000 140 SARS-CoV-2 viral copies/ $\mu$ L to determine the limit of detection (LOD) of the assay. The saliva without 141 viral particles was used as a no template control (NTC). Five (5)  $\mu$ L of saliva sample and 20  $\mu$ L of mastermix were incubated at 65°C for 30 minutes in a QuantStudio 5 Real-Time PCR machine (ThermoFisher, Waltham, MA). The specificity of optimized RT-LAMP against other coronaviruses was performed by using SARS, MERS CoV, DENV viruses as targets. To validate the amplification process, real-time fluorescence data of EvaGreen intercalating dye and ROX reference dye were recorded. The RT-LAMP amplicons were visualized via LFIA and confirmed via gel electrophoresis using a 2% agarose gel

 run at 100 V for 50 minutes, stained with ethidium bromide, and imaged using an ultraviolet light gel imaging system (c400, Azure Biosystems, Dublin, CA).

149<br>150

*2.3 Singleplex RT-LAMP for human RNA in saliva for amplification control*

 To verify the proper collection of saliva and avoid potential false-negative results due to technical errors, we searched the literature for primer sets targeting ubiquitously expressed genes in human samples. In this work, the primer set targeting human 18S rRNA (GenBank: AL592188.60) developed by Garneret et al [11] was selected (Table S1) since it resulted in consistent results. To confirm that IAC primers are orthogonal to SARS-CoV-2 primers and RNA, *in-silico* PCR validation was carried out using free software − UCSC *In-Silico* PCR [27]. The RT-LAMP of IAC was performed as described in singleplex RT-LAMP for SARS-CoV-2 detection experiment. SARS-CoV-2 spiked water, saliva sample, and total human RNA control (Applied Biosystems, Waltham, MA) were used as a template for RT-LAMP of 18S rRNA. The 5' end of LF and LB were tagged with digoxigenin (DIG) and biotin, respectively for LFIA detection. The amplification was confirmed by gel electrophoresis and the LOD was determined via LFIA. In the LOD 162 experiment, the total human RNA control was 10-fold diluted from 4.4 x  $10^6$  copies/ $\mu$ L and used as templates.

# *2.4 One-pot duplex RT-LAMP of SARS-CoV-2 and human RNA*

 The optimized duplex RT-LAMP consisted of the two sets of 10x Primer Mix targeting the ORF1ab gene or 18S rRNA in which concentrations of FIP and BIP from both sets were adjusted to 1.0 µM while the concentrations of F3, B3, LF, and LB from both sets remained the same as in the singleplex RT-LAMP conditions. Templates used in these experiments were one target and two target templates. The one target 171 template included SARS-CoV-2 spiked water and saliva without viral particles, while two target template<br>172 was SARS-CoV-2 spiked saliva. The nuclease-free water was used as NTC in this experiment. The was SARS-CoV-2 spiked saliva. The nuclease-free water was used as NTC in this experiment. The amplifications of duplex RT-LAMP were visualized on triple-line (FITC, DIG, flow control) LFIA strips. The nuclease-free water was used as the NTC to ensure that there is no contamination or cross-reactivity between two primer sets. To assess the LOD of the duplex RT-LAMP assay, saliva samples were spiked with different concentrations of SARS-CoV-2 viral particles ranging from 0 to 5000 SARS-CoV-2 viral copies/µL. The duplex RT-LAMP reactions were prepared in total volume of 50 µL with 5 µL of sample and incubated at 65°C for 30 minutes in the QuantStudio5 (Applied biosystems, Waltham, MA).

179<br>180

*2.5 Restriction enzyme digestion of duplex RT-LAMP products* 

 To validate the expected amplification products, the duplex RT-LAMP products were digested with the restriction enzyme BtsYI and Ddel that are specific to the products of SARS-CoV-2 and IAC primers, respectively. To determine restriction enzymes that specifically cut the product of SARS-CoV-2 or 18S rRNA RT-LAMP, and not both, the NEBcutter software was used [28]. The templates used in this 186 experiment included SARS-CoV-2 spiked water as SARS-CoV-2 primer product, SARS-CoV-2 free-saliva<br>187 as IAC primer product, and SARS-CoV-2 spiked saliva as duplex product. The reaction consisted of 5 µL as IAC primer product, and SARS-CoV-2 spiked saliva as duplex product. The reaction consisted of 5 µL of amplicons, 2.5 µL CutSmart Buffer (NEB, Ipswich, MA), and 1 µL of restriction enzyme. The nuclease-189 free water was added to fill up reaction volume to 25  $\mu$ L. The reactions were then incubated at 37°C in water bath for 20-30 minutes. The restriction fragments of duplex RT-LAMP products were visualized using ethidium bromide in a 2% agarose gel.

#### *2.6 Clinical sample validation*

 The developed assay was validated against frozen clinical saliva samples received from Indiana Biobank (Bloomington, IN). The saliva samples were collected in 2 mL cryovials and stored in -80°C upon arrival

in our lab. These samples were assigned as study ID 1-30, aliquoted, and used as templates for the standard

198 RT-qPCR and duplex RT-LAMP. Of 30 clinical samples, three (3) SARS-CoV-2 negative samples had<br>199 insufficient volume to extract RNA and run both RT-qPCR and duplex RT-LAMP. Therefore, additional 3 insufficient volume to extract RNA and run both RT-qPCR and duplex RT-LAMP. Therefore, additional 3 200 samples were collected from subjects who were negative for COVID-19 by using RNAPro•SAL<sup>TM</sup> (Oasis 201 Diagnostics®, Vancouver, WA) in accordance with Purdue University IRB protocol # IRB-2020-968. All 201 Diagnostics®, Vancouver, WA) in accordance with Purdue University IRB protocol # IRB-2020-968. All 202 clinical samples were heat-inactivated at 95°C for 5 minutes to ensure safety of working conditions in a 203 BSL-2 laboratory [29] and stored at −80°C until use. To validate duplex RT-LAMP against clinical samples, 204  $\frac{1}{2}$  5 or 10 µL of heat-inactivated samples were used as templates with 45 or 40 µL of RT-LAMP master mix 205 as described in one-pot duplex RT-LAMP experiment. Each sample was run in triplicate and visualized on 206 trip-line LFIAs. The samples for RT-qPCR were extracted by using the QIAamp Viral RNA Mini Kit 207 (Qiagen, Hilden, Germany) according to manufacturer's protocol. Ten  $(10)$  µL of extracted samples was used for RT-qPCR analysis using FDA authorized 2019-nCoV: Real-Time Fluorescent RT-PCR kit (BGI, 208 used for RT-qPCR analysis using FDA authorized 2019-nCoV: Real-Time Fluorescent RT-PCR kit (BGI, 209 Shenzhen, China) targeted the ORF1ab gene of SARS-CoV-2 genome and human β-actin gene as the IAC. 210 The RT-qPCR was run twice for each sample. The clinical sensitivity and specificity of duplex RT-LAMP 211 assay were evaluated as followed [30]: Sensitivity = (true positive)/(true positive + false negative); 212 Specificity = (true negative)/(true negative + false positive); Accuracy = (true positive + true negative)/(true 213 positive + true negative + false positive + false negative).

- 
- 214<br>215 216

# 215 *2.7 LFIA quantification, statistical analysis, and graphical abstract*

 The LFIA tests were run in triplicates for each experiment. The LFIA quantification and statistical analysis were performed as described by Phillips et al [31]. Briefly, after 15 mins of initial sample addition, the LFIAs were scanned using Epson V850 Pro Scanner. A custom MATLAB script was used to quantify the test band, which averages the grey-scale pixel intensity of the test band and subtracts the average background pixel intensity 40 pixels below the test band. The LOD was determined by a one-way ANOVA 222 with Dunnett's *post hoc* test with multiple comparisons using GraphPad prism (GraphPad Software, Boston, 223 MA) of the LFIA test bands of each concentration against the test bands from negative controls (no 223 MA) of the LFIA test bands of each concentration against the test bands from negative controls (no<br>224 template) with a 95% confidence interval. The graphical abstract is created in Biorender (Toronto, Canada). template) with a 95% confidence interval. The graphical abstract is created in Biorender (Toronto, Canada).

225

# 226 3. **Results and discussion**

227

# 228 *3.1 Analytical sensitivity and specificity of SARS-CoV-2 RT-LAMP assay in saliva samples*

229 Throughout the stages of infection, the viral load can be as low  $10^3$  to  $10^5$  copies/mL of saliva sample<br>231 (equivalent to 1 to 100 copies/ $\mu$ L of saliva) in early stage and spiked to  $10^8$  copies/mL  $(10^5$  copies 231 (equivalent to 1 to 100 copies/ $\mu$ L of saliva) in early stage and spiked to 10<sup>8</sup> copies/mL (10<sup>5</sup> copies/ $\mu$ L) in later stage [32]. To evaluate the analytical sensitivity of SARS-CoV-2 RT-LAMP assay, saliva spiked with various concentration of inactivated SARS-CoV-2 particles was used as templates. The time to detection of SARS-CoV-2 in the RT-LAMP assay was displayed as the cycle threshold (Ct) value against various concentrations of SARS-CoV-2. The singleplex RT-LAMP targeting ORF1ab gene was able to detect as few as 100 SARS-CoV-2 viral copies/µL saliva in less than 30 minutes (Figure 1A). The SARS-CoV-2 237 RT-LAMP products visualized by gel electrophoresis were in a ladder-like pattern (Figure 1B), indicating the successful production of the different length concatemers. The conjugation of the backward loop primer the successful production of the different length concatemers. The conjugation of the backward loop primer to biotin and the forward loop primer to FITC allowed the result to be readout on LFIAs. The test line of 240 saliva samples with SARS-CoV-2 concentration of 100, 500, and 5000 viral copies/µL were observed (Figure 1C). The presence of the flow control line in all samples suggested that the flow of samples on LFIAs was effective. The analytical sensitivity or LOD of the assay was determined by quantifying test band intensity of each concentration. The custom MATLAB script calculates the average gray-scale pixel intensity of the test band and then subtracts the average background pixel intensity located 40 pixels below the test band. As shown in Figure 1D, there is a statistically significant difference in test band intensity of 246 RT-LAMP products from 100-5000 viral copies/ $\mu$ L in saliva as compared to no template control when using a one-way ANOVA with Dunnett's *post hoc*. The analysis of gel electrophoresis and LFIAs suggested 248 that our SARS-CoV-2 RT-LAMP assay exhibit the LOD of 100 viral copies/µL saliva, which is in the range

 of clinically relevant LOD [32]. Moreover, the developed RT-LAMP assay was specific to SARS-CoV-2 RNA and demonstrated no amplified products in the gel nor test band on LFIAs when viral particles from 251 MERS, DENV1, or CoV were used as a template (Figure S1). Taken together, the RT-LAMP assay in saliva is both sensitive and specific for SARS-coV-2 detection. saliva is both sensitive and specific for SARS-coV-2 detection.





**Figure 1.** Analytical sensitivity of SARS-CoV-2 RT-LAMP assay in saliva. Ct value of SARS-CoV-2 RT-LAMP in various concentrations (A). RT-LAMP based detection of inactivated viral particles as visualized on gel electrophoresis (B) LFIA (C), and corresponding test band intensity analysis (D).  $n = 3$ ; \*\*\*\* indicates p value  $\leq 0.0001$ . The ladder-like bands on gel electrophoresis indicating successful amplification.

#### *3.2 RT-LAMP of 18S ribosomal RNA IAC specific to human RNA in saliva*

 IACs are one of the required controls according to the US FDA guideline for *in vitro* diagnostic devices for various infectious diseases provided to the industry [3]. Given that saliva is the selected sample matrix for the study, we screened for human genes that are expected to be ubiquitously expressed in human saliva to use as the IAC target. Regardless of the presence of target pathogen, the IAC should be detectable in all samples. Another criterion for IAC in this work is that the IAC primers and target should not cross-react with SARS-CoV-2 primers, or the SAR-CoV-2 target. No matches were found when conducting an *in- silico* analysis of PCR using primers designed for the 18S rRNA against the SARS-CoV-2 genome and primers (Figure S2). This result suggested that IAC primers are orthogonal to SARS-CoV-2 primers and RNA. The amplification plot of 18S rRNA RT-LAMP in Figure 2A demonstrates that sigmoidal curve of 266 the fluorescence signal showed up only when the positive control — total human RNA control and saliva were used as the templates. The amplicons were subsequently analyzed by the gel electrophoresis. As seen in Figure 2B, the gel image displayed the ladder-like bandings when total human RNA control and saliva were used as templates. In contrast, no products were seen on the gel when the template was SARS-CoV-

 2 particles without saliva. This result confirms that 18S rRNA primers were specific to human RNA control and saliva sample and there is no cross-reactivity against SARS-CoV-2. Therefore, the primer set targeting 272 human 18S rRNA was chosen and incorporated in duplex RT-LAMP as the IAC. It is worth noting that the amount of human 18S rRNA in human saliva can vary depending on several factors including collection amount of human 18S rRNA in human saliva can vary depending on several factors including collection method used and the time of day the sample was collected. We ran the LOD of 18S rRNA RT-LAMP and found that the LOD of the assay was 4,400 copies/µL (Figure S3), which is in the range of reported concentrations of 18S rRNA in human saliva by other groups [33].

 In addition to SARS-CoV-2, saliva could serve as specimen for other respiratory viruses [34] such as Influenza viruses, Respiratory Syncytial Virus (RSV), Adenovirus, and Rhinovirus and even bacterial 279 pathogens such as Group A streptococci causing strep throat, and *Bordetella pertussis* causing whooping cough [35]. This study suggests that the 18S rRNA could be a suitable IAC for other diagnostic tests that cough [35]. This study suggests that the 18S rRNA could be a suitable IAC for other diagnostic tests that rely on saliva samples. Moreover, this knowledge could also be similarly employed for integrated IACs in other clinical sample matrixes such as urine, nasal swabs, and blood. Kretschmer-Kazemi Far et al reported that 18S rRNA is the most abundant RNA species in urine samples [36] and Garneret et al. reported the use of 18S rRNA as the IAC for nasal swabs [11]. By performing 18S rRNA RT-LAMP using whole blood (five (5) µL of undiluted blood), we also demonstrated that 18S rRNA was detectable in freshly collected blood samples (Figure S4.)



**Figure 2.** Specificity of IAC primer. Amplification plot (A) and gel electrophoresis (B) of human 18S rRNA RT-LAMP using different templates. The ladder-like bands indicating successful amplification are only present when saliva and human RNA were used as templates.  $N = 2$ .

*3.3 Optimization of one-pot duplex RT-LAMP of SARS-CoV-2 and IAC* 

 In general, a one-pot multiplexed reaction can simplify the assay workflow and reduce the amount of sample 293 and reagents required. It can also minimize the risk of cross-contamination between reaction zones and improve the overall assay efficiency. However, a one-pot multiplexed reaction can be more challenging to improve the overall assay efficiency. However, a one-pot multiplexed reaction can be more challenging to

optimize, and the different targets may compete for limited resources, such as enzymes or primers [37].

296 Therefore, the choices of primers, concentrations, and assay control template are critical to the optimization<br>297 process. The duplex RT-LAMP of SARS-CoV-2 and IAC consisting of 2 sets targeting the ORF1ab gene process. The duplex RT-LAMP of SARS-CoV-2 and IAC consisting of 2 sets targeting the ORF1ab gene 298 and 18S rRNA was performed in a single tube "one-pot reaction". Different template setups were used to examine the interactions between additional primer sets and their cross-reactivities. The successful examine the interactions between additional primer sets and their cross-reactivities. The successful amplification of sample containing one target (SARS-CoV-2 spiked water (W+) and saliva without viral particles (S-)) and two targets (SARS-CoV-2 spiked saliva (S+) are shown on the amplification plot (Figure 3A) and gel electrophoresis (Figure 3B). The NTC showed no banding on the gel, confirming that there was no non-specific amplification or primer-dimers. As seen in Figure 3A, the presence of saliva in SARS- CoV-2 spiked saliva sample (S+) slowed down the amplification of SARS-CoV-2 primers as compared to SARS-CoV-2 in water (W+). This is likely due to factors in the complex matrices such as saliva that interfere with the activity of the enzymes, degrade or inhibit the RNA template or primers, or increase the interfere with the activity of the enzymes, degrade or inhibit the RNA template or primers, or increase the viscosity of the reaction mixture [38]. The delayed amplification is not specific to the multiplex RT-LAMP primer set used here and has been observed before when complex matrices were introduced into LAMP reaction [39]. The amplicons from different conditions were visualized on a gel were added to LFIAs (Figure 3C). Without templates of both primer sets (NTC) on the W- strip, only the flow control line was present. As anticipated, the W+ strip showed the flow control and test lines, while the S- strip displayed the flow control and IAC lines (Figure 3C). The amplicons of both primers were present on the S+ strip, indicating the successful duplexed RT-LAMP of the target pathogen and IAC in one-pot reaction (n=3). This duplex reaction demonstrates the multiplexing capabilities of 18S rRNA and the ORF1ab gene of SARS-CoV-2 in human saliva in the one-pot reaction platform (Figure 3). 316



**Figure 3.** One-pot duplex RT- LAMP of SARS-CoV-2 and human 18S rRNA. (A) Amplification plot of duplex RT-LAMP using different templates. (B) Gel electrophoresis and (C) corresponding LFIAs of optimized assay (n=3). Integration of 18S rRNA human sample control into duplex RT-LAMP assay demonstrating differentiation between saliva (with 18S rRNA) and water matrix (without 18S rRNA) and SARS-CoV-2 spiked into each matrix. W- and W+ represent water with and without SARS-CoV-2, respectively. S- and S+ represent saliva sample with and without SARS-CoV-2, respectively. (D)

Restriction enzyme digestion of duplex RT-LAMP of SARS-CoV-2 and human 18S rRNA visualized on the gel. Red boxes indicate BstYI digested amplicon with the characteristic band at 110 bp and blue boxes indicate DdeI digested amplicon the characteristic band at 150 bp. Ø indicate non-digested amplicons.

#### *3.4 Validation of the duplex RT-LAMP products by restriction enzyme digestion*

- The amplification products of the two primer sets in the duplex RT-LAMP were also confirmed by restriction enzyme digestion by using two specific restriction enzymes: BtsYI, which targets the product of SARS-CoV-2 primers, and Ddel, which targets the IAC primers (Figure 3D). The digested and non-digested amplicons of SARS-CoV-2, 18S rRNA, and duplex products were shown in Figure 3D. For SARS-CoV-2 product (SARS-CoV-2 spiked water), the anticipated 110 bp band was observed after BtsYI digestion as seen in lane 2 on the gel. This band did not show up in non-digested SARS-CoV-2 product in lane 1. In case of 18S rRNA product from saliva without SARS-CoV-2, the characteristic band at approximately 150 bp was observed when the amplicons were digested with DdeI as shown in lane 4. In lane 3 of non-digested product, the band at 150 bp was absent. Once the duplex RT-LAMP products from SARS-CoV-2 spiked saliva were digested with BtsYI and DdeI, the characteristic band at 110 bp and 150 bp were visible on the gel in lane 6 and lane 7, respectively, along with smear bands of undigested amplicons. This experiment confirms that the duplex RT-LAMP assay could amplify two targets in the one-pot reaction without cross-reactivity.
- 

# *3.5 Analytical sensitivity of duplex RT-LAMP assay of SARS-CoV-2 and IAC*

335<br>336 The LOD of the duplex RT-LAMP assay was determined by detecting different concentrations of SARS- CoV-2 spiked into saliva, as was performed in the singleplex SARS-CoV-2 RT-LAMP assay. As seen in Figure 4A, the IAC line showed up in all samples due to the presence of intact human 18S RNA in saliva. The leftmost strip of no viral particles represented a valid negative result. The strips of concentrations ranging from 100-5000 viral copies/µL demonstrated 3 lines: flow control, IAC, and SARS-CoV-2 test lines. Figure 4B demonstrates that there is a statistically significantly difference in the test band of duplex 342 RT-LAMP products ranging from 100-5000 viral copies/µL compared to no template, as confirmed by a one-way ANOVA with Dunnett's *post hoc* analysis. As a result, the duplex RT-LAMP exhibited a LOD of 100 viral copies/µL saliva comparable to single plex SARS-CoV-2 RT-LAMP. With prior heat-inactivation 345 of saliva samples, we could bring the LOD down to 50 viral copies/ $\mu$ L (Figure S5). Moreover, we found that the IAC line intensity demonstrated a statistically significant decrease as the concentration of SARSthat the IAC line intensity demonstrated a statistically significant decrease as the concentration of SARS- CoV-2 in the sample was increased. On the other hand, the SARS-CoV-2 test line intensity increased in a concentration-dependent manner. Importantly, while the IAC line remained visible in all tests, we hypothesize that in cases of exceptionally high viral loads of SARS-CoV-2, the viral target could 350 outcompete the IAC in samples. This would lead to the absence of IAC at excess SARS-CoV-2<br>351 concentrations. In this case, users would be informed to interpret any result with a SARS-CoV-2 line as a 351 concentrations. In this case, users would be informed to interpret any result with a SARS-CoV-2 line as a<br>352 positive result. The LODs of SARS-CoV-2 RT-LAMP assays can vary depending on several factors such positive result. The LODs of SARS-CoV-2 RT-LAMP assays can vary depending on several factors such as the type of assay used, the quality of the sample, and the target genes selected for amplification. As compared to several studies that have reported LODs of SARS-Cov-2 ranging from 10 to 1000 viral copies/µL [40–43], our duplex RT-LAMP could detect both targets without compromising the sensitivity of SARS-CoV-2 primers.



**Figure 4.** Analytical sensitivity of duplex RT-LAMP assay of SARS-CoV-2 and IAC in saliva visualized on (A) LFIA and (B) corresponding test band intensity analysis.  $n = 3$ ; \*/# indicates p value  $\leq 0.05$ ; \*\*/## indicates  $p \le 0.01$ ; \*\*\*/### indicates p value  $\le 0.001$ ; compared to equivalent bands at 0 viral copies/ $\mu$ L.

358<br>359

359 *3.6 Clinical sample validation*

360

 Clinical sample validation is crucial for the successful implementation of diagnostic assays into clinical practice. It ensures that the assay is accurate, reliable, and can be used to make informed decisions about patient care. To evaluate clinical performance of our assay, we tested 30 deidentified clinical samples received from the Indiana Biobank. Since we intend to implement this assay at point-of-care sites, we bypassed any RNA extraction steps and validated the duplex assay by using non-extracted samples. The duplex RT-LAMP assays were run in triplicates for each sample and the results were interpreted on triple- line LFIAs. All LFIA results and quantified test line intensities are shown in Figure S6, Figure S7, and Table S2. We found that the IAC lines were observed in all samples although the IAC lines of non-extracted sample ID 10 were faint. Therefore, we ran the assay again with extracted samples and found that the IAC lines showed up clearly from this extracted sample ID 10 (Figure S5.) and Ct value of 22 obtained from 371 RT-PCR indicated very high viral load [44]. Saliva sample ID 19 was highly viscous. Therefore, we diluted this sample with the nuclease-free water in a 1:1 ratio before adding to the reaction. Sample dilution is one this sample with the nuclease-free water in a 1:1 ratio before adding to the reaction. Sample dilution is one of sample preparation methods for diagnostic tests that has been shown to help reduce inhibitory factors and viscosity of sample matrices [42].

375

376 The RT-PCR assay of all 30 extracted samples was analyzed as a reference method. The Ct values were 377 used as a parameter for result interpretation according to manufacture (Table S3). The clinical sensitivity 378 and specificity of the RT-PCR kit were shown in Table 2. The results suggest that our duplex RT-LAMP assay with non-extracted samples correctly identified 20 of the 21 RT-PCR-positive samples and accurately assay with non-extracted samples correctly identified 20 of the 21 RT-PCR–positive samples and accurately 380 detected all 9 SARS-CoV-2 negative specimens. Only non-extracted sample ID 6 was identified as negative 381 while the RT-PCR identified as positive. Sample ID 6 had an RT-PCR Ct value of 33, which is considered 382 to be a very low viral load [45]. When RNA was extracted from sample ID 6, the RT-LAMP assay correctly 383 identified the sample as positive. In general, the viral load of SARS-CoV-2 in saliva may vary throughout 384 the different stages of infection. The study conducted by Juanola-Falgarona et al. shows that the viral load<br>385 of SARS-CoV-2 in clinical samples exhibited linear relationship with Ct value. The lowest concentration of SARS-CoV-2 in clinical samples exhibited linear relationship with Ct value. The lowest concentration 386 of 1.00E+02 copies/mL corresponded to Ct value of  $34.9 \pm 3$ , while the highest concentration of 1.00E+06<br>387 corresponded to Ct value of 23.4  $\pm$  0.7 [46]. corresponded to Ct value of 23.4  $\pm$  0.7 [46].

388

389 On non-extracted saliva samples, the duplex RT-LAMP achieves 95% clinical sensitivity, 100% clinical specificity, and 96% accuracy. These are considered well above the acceptable values according to the US specificity, and 96% accuracy. These are considered well above the acceptable values according to the US

- 391 Food and Drug Administration (FDA) guidance for SARS-CoV-2 diagnostic tests Emergency Use
- 392 Authorization .

#### 393

### **Table 2.** Calculation of sensitivity and specificity for the Duplex RT-LAMP



TP: True positive, FP: False positive, FN: False negative, TN: True negative

# 394

# 395 **4. Conclusion**

396

397 We successfully combined an IAC for clinically valid sample collection and assay function with a test for 398 the SARS-CoV-2 virus from saliva using the one-pot duplex RT-LAMP. The test can detect both the target 399 virus (SARS-CoV-2) and IAC in the same reaction without cross-reactivity. Without requiring RNA<br>400 extraction, the duplex RT-LAMP assay was able to detect SARS-CoV-2 down to 100 copies/uL of saliva 400 extraction, the duplex RT-LAMP assay was able to detect SARS-CoV-2 down to 100 copies/ $\mu$ L of saliva 401 within 30 minutes, or 50 copies/ $\mu$ L with an additional heat inactivation step. The developed assay exhibited within 30 minutes, or 50 copies/μL with an additional heat inactivation step. The developed assay exhibited 402 95% clinical sensitivity and 100% specificity with accuracy of 96% on non-extracted saliva samples 403 without heat inactivation. IACs are integral to ensure the accuracy and reliability and user confidence in 404 molecular diagnostics in order to run them at home and at POC sites with minimally trained users. 405 Additionally, both the specific 18S rRNA IAC and general knowledge of duplex RT-LAMP can be applied 406 in similar manner to incorporate IACs into various other clinical sample matrices including blood, urine,<br>407 and nasal swabs. This work is a promising step toward an integrated sample-to-answer POC device for 407 and nasal swabs. This work is a promising step toward an integrated sample-to-answer POC device for 408 respiratory infection detection at home or POC sites. respiratory infection detection at home or POC sites.

409

# 410 **CRediT authorship contribution statement**

- 411
- 412 Navaporn Sritong: Conceptualization, Methodology, Investigation, Validation, Writing original draft
- 413 Winston Wei Ngo: Methodology, Investigation,<br>414 Karin F. K. Ejendal: Methodology, Writing rev
- 414 Karin F. K. Ejendal: Methodology, Writing review & editing.<br>415 Jacqueline C. Linnes: Conceptualization, Writing-review & edit
- Jacqueline C. Linnes: Conceptualization, Writing-review & editing, Supervision, Funding acquisition.

# 416

- 417 **Declaration of competing interest**
- 418
- 419 Jacqueline C. Linnes is co-founder of EverTrue LLC, a diagnostics company developing paper-based POC<br>420 NAATs, and co-founder of OmniVis Inc. NAAT company developing POC diagnostics. Navaporn Sritong,
- NAATs, and co-founder of OmniVis Inc. NAAT company developing POC diagnostics. Navaporn Sritong,
- 421 Winston Wei Ngo, and Karin F. K. Ejendal have declared that they have no competing interests.

#### 422<br>423 423 **Acknowledgement**

- 424
- 425 This study received financial support from the Moore Inventor Fellows Award from the Gordon and Betty
- 426 Moore Foundation Award #9687 and from NIH National Institute on Drug Abuse award #
- 427 DP2DA051910. We would like to recognize Dr. Mohit Verma, Assistant Professor in Agricultural and
- 428 Biological Engineering, Purdue University, for providing information on SARS-CoV-2 primer sequences.
- 429<br>430

# 430 **Appendix A. Supplementary data**

- 431 432 **Data availability**
- 433
- 434 No data was used for the research described in the article.
- 435 436

#### 437<br>438 **References**

- 
- [1] N.V. Tolan, G.L. Horowitz, Clinical Diagnostic Point-of-Care Molecular Assays for SARS-CoV-2, Clin. Lab. Med. 42 (2022) 223–236. https://doi.org/10.1016/j.cll.2022.03.002.
- [2] J.L.V. Shaw, Practical challenges related to point of care testing, Pract. Lab. Med. 4 (2016) 22–29. 443 https://doi.org/10.1016/j.plabm.2015.12.002.<br>444 [3] Class II Special Controls Guideline: In Vitro D
- [3] Class II Special Controls Guideline: In Vitro Diagnostic Devices for Bacillus spp. Detection, (n.d.).
- [4] K.G. Shah, S. Kumar, P. Yager, Near-digital amplification in paper improves sensitivity and speed in biplexed reactions, Sci. Rep. 12 (2022) 14618. https://doi.org/10.1038/s41598-022-18937-8.
- [5] C. Schrader, A. Schielke, L. Ellerbroek, R. Johne, PCR inhibitors occurrence, properties and removal,
- 448 J. Appl. Microbiol. 113 (2012) 1014–1026. https://doi.org/10.1111/j.1365-2672.2012.05384.x.<br>449 [6] U.S. Department of Health and Human Services, Food and Drug Administration, Class II S 449 [6] U.S. Department of Health and Human Services, Food and Drug Administration, Class II Special<br>450 **Controls Guideline: Nucleic Acid Amplification Assays for the Detection of Trichomonas vaginalis-** Controls Guideline: Nucleic Acid Amplification Assays for the Detection of Trichomonas vaginalis- Guideline for Industry and Food and Drug Administration Staff, n.d. https://fda.report/media/92927/Class-II-Special-Controls-Guideline--Nucleic-Acid-Amplification- Assays-for-the-Detection-of-Trichomonas-vaginalis---Guideline-for-Industry-and-Food-and-Drug-Administration-Staff.pdf.
- [7] S. Garg, L. Kim, M. Whitaker, A. O'Halloran, C. Cummings, R. Holstein, M. Prill, S.J. Chai, P.D. 456 Kirley, N.B. Alden, B. Kawasaki, K. Yousey-Hindes, L. Niccolai, E.J. Anderson, K.P. Openo, A.<br>457 Weigel, M.L. Monroe, P. Ryan, J. Henderson, S. Kim, K. Como-Sabetti, R. Lynfield, D. Sosin, S. Weigel, M.L. Monroe, P. Ryan, J. Henderson, S. Kim, K. Como-Sabetti, R. Lynfield, D. Sosin, S. Torres, A. Muse, N.M. Bennett, L. Billing, M. Sutton, N. West, W. Schaffner, H.K. Talbot, C. Aquino, A. George, A. Budd, L. Brammer, G. Langley, A.J. Hall, A. Fry, Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020, MMWR Morb. Mortal. Wkly. Rep. 69 (2020) 458–464. https://doi.org/10.15585/mmwr.mm6915e3.
- [8] A.D. Subali, L. Wiyono, Reverse Transcriptase Loop Mediated Isothermal Amplification (RT-LAMP) for COVID-19 diagnosis: a systematic review and meta-analysis, Pathog. Glob. Health. 115 (n.d.) 281–291. https://doi.org/10.1080/20477724.2021.1933335.
- [9] M.N. Anahtar, G.E.G. McGrath, B.A. Rabe, N.A. Tanner, B.A. White, J.K.M. Lennerz, J.A. Branda, C.L. Cepko, E.S. Rosenberg, Clinical Assessment and Validation of a Rapid and Sensitive SARS- CoV-2 Test Using Reverse Transcription Loop-Mediated Isothermal Amplification Without the Need for RNA Extraction, Open Forum Infect. Dis. 8 (2021) ofaa631. https://doi.org/10.1093/ofid/ofaa631.
- 470 [10] Y. Zhang, G. Ren, J. Buss, A.J. Barry, G.C. Patton, N.A. Tanner, Enhancing colorimetric loop-471 mediated isothermal amplification speed and sensitivity with guanidine chloride, BioTechniques. 69<br>472 (2020) 178–185. https://doi.org/10.2144/btn-2020-0078. (2020) 178–185. https://doi.org/10.2144/btn-2020-0078.
- [11] P. Garneret, E. Coz, E. Martin, J.-C. Manuguerra, E. Brient-Litzler, V. Enouf, D.F.G. Obando, J.-C. Olivo-Marin, F. Monti, S. van der Werf, J. Vanhomwegen, P. Tabeling, Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification, PLOS ONE. 16 (2021) e0243712. https://doi.org/10.1371/journal.pone.0243712.
- [12] G. Papadakis, A.K. Pantazis, N. Fikas, S. Chatziioannidou, V. Tsiakalou, K. Michaelidou, V. Pogka, M. Megariti, M. Vardaki, K. Giarentis, J. Heaney, E. Nastouli, T. Karamitros, A. Mentis, A. Zafiropoulos, G. Sourvinos, S. Agelaki, E. Gizeli, Portable real-time colorimetric LAMP-device for rapid quantitative detection of nucleic acids in crude samples, Sci. Rep. 12 (2022) 3775. 481 https://doi.org/10.1038/s41598-022-06632-7.<br>482 [13]B.A. Rabe, C. Cepko, SARS-CoV-2 detection
- [13] B.A. Rabe, C. Cepko, SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive protocol for sample inactivation and purification, Proc. Natl. Acad. Sci. 117 (2020) 24450–24458. https://doi.org/10.1073/pnas.2011221117.
- [14] O. Yaren, J. McCarter, N. Phadke, K.M. Bradley, B. Overton, Z. Yang, S. Ranade, K. Patil, R. Bangale, 486 S.A. Benner, Ultra-rapid detection of SARS-CoV-2 in public workspace environments, PLOS ONE.<br>487 16 (2021) e0240524. https://doi.org/10.1371/journal.pone.0240524. 16 (2021) e0240524. https://doi.org/10.1371/journal.pone.0240524.

- 488 [15] J.P. Broughton, X. Deng, G. Yu, C.L. Fasching, V. Servellita, J. Singh, X. Miao, J.A. Streithorst, A.<br>489 Granados, A. Sotomayor-Gonzalez, K. Zorn, A. Gopez, E. Hsu, W. Gu, S. Miller, C.-Y. Pan, H. Granados, A. Sotomayor-Gonzalez, K. Zorn, A. Gopez, E. Hsu, W. Gu, S. Miller, C.-Y. Pan, H. 490 Guevara, D.A. Wadford, J.S. Chen, C.Y. Chiu, CRISPR–Cas12-based detection of SARS-CoV-2,<br>491 Mat. Biotechnol. 38 (2020) 870–874. https://doi.org/10.1038/s41587-020-0513-4. Nat. Biotechnol. 38 (2020) 870–874. https://doi.org/10.1038/s41587-020-0513-4.
- [16] S.H. Lee, Y.H. Baek, Y.-H. Kim, Y.-K. Choi, M.-S. Song, J.-Y. Ahn, One-Pot Reverse Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) for Detecting MERS-CoV, Front. Microbiol. 7 (2016) 2166. https://doi.org/10.3389/fmicb.2016.02166.
- [17] C. for D. and R. Health, In Vitro Diagnostics EUAs Molecular Diagnostic Tests for SARS-CoV-2, 496 FDA. (2023). https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-<br>497 medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2 (accessed June 5, medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2 (accessed June 5, 2023).
- 499 [18] C. Amaral, W. Antunes, E. Moe, A.G. Duarte, L.M.P. Lima, C. Santos, I.L. Gomes, G.S. Afonso, R. Vieira, H.S.S. Teles, M.S. Reis, M.A.R. da Silva, A.M. Henriques, M. Fevereiro, M.R. Ventura, M. Serrano, C. Pimentel, A molecular test based on RT-LAMP for rapid, sensitive and inexpensive colorimetric detection of SARS-CoV-2 in clinical samples, Sci. Rep. 11 (2021) 16430. https://doi.org/10.1038/s41598-021-95799-6.
- [19] S.A. El-Kafrawy, M.M. El-Daly, A.M. Hassan, S.M. Harakeh, T.A. Alandijany, E.I. Azhar, Rapid and Reliable Detection of SARS-CoV-2 Using Direct RT-LAMP, Diagnostics. 12 (2022) 828. https://doi.org/10.3390/diagnostics12040828.
- [20] M. Inaba, Y. Higashimoto, Y. Toyama, T. Horiguchi, M. Hibino, M. Iwata, K. Imaizumi, Y. Doi, Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection, Int. J. Infect. Dis. 107 (2021) 195–200. https://doi.org/10.1016/j.ijid.2021.04.018.
- [21] J.H. Kim, M. Kang, E. Park, D.R. Chung, J. Kim, E.S. Hwang, A Simple and Multiplex Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid Detection of SARS-CoV, Biochip J. 13 (2019) 341–351. https://doi.org/10.1007/s13206-019-3404-3.
- [22] Y. Shao, S. Zhu, C. Jin, F. Chen, Development of multiplex loop-mediated isothermal amplification- RFLP (mLAMP-RFLP) to detect Salmonella spp. and Shigella spp. in milk, Int. J. Food Microbiol. 148 (2011) 75–79. https://doi.org/10.1016/j.ijfoodmicro.2011.05.004.
- [23] E.C. Kline, N. Panpradist, I.T. Hull, Q. Wang, A.K. Oreskovic, P.D. Han, L.M. Starita, B.R. Lutz, Multiplex Target-Redundant RT-LAMP for Robust Detection of SARS-CoV-2 Using Fluorescent Universal Displacement Probes, Microbiol. Spectr. 10 (2022) e01583-21. https://doi.org/10.1128/spectrum.01583-21.
- [24] E. Pasomsub, S.P. Watcharananan, K. Boonyawat, P. Janchompoo, G. Wongtabtim, W. Suksuwan, S. Sungkanuparph, A. Phuphuakrat, Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study, Clin. Microbiol. Infect. 27 (2021) 285.e1-285.e4. https://doi.org/10.1016/j.cmi.2020.05.001.
- [25] A. Langedijk, O. Allicock, M.V. Wijk, D. Yolda-Carr, D. Weinberger, A. Wyllie, L. Bont, Saliva as 525 an alternative to nasopharyngeal swabs for detection of respiratory syncytial virus (RSV) in children,<br>526 Eur. Respir. J. 60 (2022). https://doi.org/10.1183/13993003.congress-2022.4519.
- 526 Eur. Respir. J. 60 (2022). https://doi.org/10.1183/13993003.congress-2022.4519.<br>527 [26] K.K.W. To, C.C.Y. Yip, C.Y.W. Lai, C.K.H. Wong, D.T.Y. Ho, P.K.P. Pang, A.C. [26] K.K.W. To, C.C.Y. Yip, C.Y.W. Lai, C.K.H. Wong, D.T.Y. Ho, P.K.P. Pang, A.C.K. Ng, K.-H. Leung, R.W.S. Poon, K.-H. Chan, V.C.C. Cheng, I.F.N. Hung, K.-Y. Yuen, Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study, Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 25 (2019) 372–378. https://doi.org/10.1016/j.cmi.2018.06.009.
- [27] L.R. Nassar, G.P. Barber, A. Benet-Pagès, J. Casper, H. Clawson, M. Diekhans, C. Fischer, J.N. Gonzalez, A.S. Hinrichs, B.T. Lee, C.M. Lee, P. Muthuraman, B. Nguy, T. Pereira, P. Nejad, G. Perez, B.J. Raney, D. Schmelter, M.L. Speir, B.D. Wick, A.S. Zweig, D. Haussler, R.M. Kuhn, M. Haeussler, W.J. Kent, The UCSC Genome Browser database: 2023 update, Nucleic Acids Res. 51 (2023) D1188–D1195. https://doi.org/10.1093/nar/gkac1072.
- [28] NEBcutter 3.0, (n.d.). https://nc3.neb.com/NEBcutter/ (accessed May 25, 2023).

- [29] C. Batéjat, Q. Grassin, J.-C. Manuguerra, I. Leclercq, Heat inactivation of the severe acute respiratory syndrome coronavirus 2, J. Biosaf. Biosecurity. 3 (2021) 1–3. 540 https://doi.org/10.1016/j.jobb.2020.12.001.<br>541 [30]R. Parikh, A. Mathai, S. Parikh, G. Chandra
- [30] R. Parikh, A. Mathai, S. Parikh, G. Chandra Sekhar, R. Thomas, Understanding and using sensitivity, specificity and predictive values, Indian J. Ophthalmol. 56 (2008) 45–50.
- [31] E.A. Phillips, Stimuli-Responsive Valving Mechanisms for Paper-Based Diagnostics, thesis, Purdue University Graduate School, 2020. https://doi.org/10.25394/PGS.11949231.v1.
- [32] E.S. Savela, A. Viloria Winnett, A.E. Romano, M.K. Porter, N. Shelby, R. Akana, J. Ji, M.M. Cooper, N.W. Schlenker, J.A. Reyes, A.M. Carter, J.T. Barlow, C. Tognazzini, M. Feaster, Y.-Y. Goh, R.F. 547 Ismagilov, Quantitative SARS-CoV-2 Viral-Load Curves in Paired Saliva Samples and Nasal Swabs<br>548 Inform Appropriate Respiratory Sampling Site and Analytical Test Sensitivity Required for Earliest Inform Appropriate Respiratory Sampling Site and Analytical Test Sensitivity Required for Earliest Viral Detection, J. Clin. Microbiol. 60 (2022) e0178521. https://doi.org/10.1128/JCM.01785-21.
- [33] P. Ostheim, A. Tichý, I. Sirak, M. Davidkova, M.M. Stastna, G. Kultova, T. Paunesku, G. Woloschak, M. Majewski, M. Port, M. Abend, Overcoming challenges in human saliva gene expression measurements, Sci. Rep. 10 (2020) 11147. https://doi.org/10.1038/s41598-020-67825-6.
- [34] K.K. To, L. Lu, C.C. Yip, R.W. Poon, A.M. Fung, A. Cheng, D.H. Lui, D.T. Ho, I.F. Hung, K.-H. 554 Chan, K.-Y. Yuen, Additional molecular testing of saliva specimens improves the detection of respiratory viruses, Emerg. Microbes Infect. 6 (2017) e49. https://doi.org/10.1038/emi.2017.35. respiratory viruses, Emerg. Microbes Infect. 6 (2017) e49. https://doi.org/10.1038/emi.2017.35.
- [35] W. Tu, A.M. McManamen, X. Su, I. Jeacopello, M.G. Takezawa, D.L. Hieber, G.W. Hassan, U.N. Lee, E.V. Anana, M.P. Locknane, M.W. Stephenson, V.A.M. Shinkawa, E.R. Wald, G.P. DeMuri, K.N. Adams, E. Berthier, S. Thongpang, A.B. Theberge, At-Home Saliva Sampling in Healthy Adults Using CandyCollect, a Lollipop-Inspired Device, Anal. Chem. 95 (2023) 10211–10220. https://doi.org/10.1021/acs.analchem.3c00462.
- [36] R. Kretschmer-Kazemi Far, K. Frank, G. Sczakiel, Sampling, Logistics, and Analytics of Urine for RT-qPCR-based Diagnostics, Cancers. 13 (2021) 4381. https://doi.org/10.3390/cancers13174381.
- [37] J. Parker, N. Fowler, M.L. Walmsley, T. Schmidt, J. Scharrer, J. Kowaleski, T. Grimes, S. Hoyos, J. Chen, Analytical Sensitivity Comparison between Singleplex Real-Time PCR and a Multiplex PCR Platform for Detecting Respiratory Viruses, PLOS ONE. 10 (2015) e0143164. https://doi.org/10.1371/journal.pone.0143164.
- 567 [38] Z. Li, J.L. Bruce, B. Cohen, C.V. Cunningham, W.E. Jack, K. Kunin, B.W. Langhorst, J. Miller, R.A. Moncion, C.B. Poole, P.K. Premsrirut, G. Ren, R.J. Roberts, N.A. Tanner, Y. Zhang, C.K.S. Carlow, Development and implementation of a simple and rapid extraction-free saliva SARS-CoV-2 RT- LAMP workflow for workplace surveillance, PLOS ONE. 17 (2022) e0268692. https://doi.org/10.1371/journal.pone.0268692.
- [39] T.J. Moehling, Portable platforms for molecular-based detection of pathogens in complex sample matrices, thesis, Purdue University Graduate School, 2020. https://doi.org/10.25394/PGS.12739466.v1.
- [40] R. Lu, X. Wu, Z. Wan, Y. Li, X. Jin, C. Zhang, A Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2, Int. J. Mol. Sci. 21 (2020) 2826. https://doi.org/10.3390/ijms21082826.
- [41] J. Lim, R. Stavins, V. Kindratenko, J. Baek, L. Wang, K. White, J. Kumar, E. Valera, W.P. King, R. Bashir, Microfluidic point-of-care device for detection of early strains and B.1.1.7 variant of SARS-CoV-2 virus, Lab. Chip. 22 (2022) 1297–1309. https://doi.org/10.1039/D2LC00021K.
- [42] J.L. Davidson, J. Wang, M.K. Maruthamuthu, A. Dextre, A. Pascual-Garrigos, S. Mohan, S.V.S. Putikam, F.O.I. Osman, D. McChesney, J. Seville, M.S. Verma, A paper-based colorimetric molecular test for SARS-CoV-2 in saliva, Biosens. Bioelectron. 9 (2021) 100076. https://doi.org/10.1016/j.biosx.2021.100076.
- [43] A.J. Colbert, D.H. Lee, K.N. Clayton, S.T. Wereley, J.C. Linnes, T.L. Kinzer-Ursem, PD-LAMP smartphone detection of SARS-CoV-2 on chip, Anal. Chim. Acta. 1203 (2022) 339702. https://doi.org/10.1016/j.aca.2022.339702.

- 588 [44] F. Yu, L. Yan, N. Wang, S. Yang, L. Wang, Y. Tang, G. Gao, S. Wang, C. Ma, R. Xie, F. Wang, C. 589 [44] F. Zhu, Y. Guo, F. Zhang, Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Tan, L. Zhu, Y. Guo, F. Zhang, Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in 590 Infected Patients, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 71 (2020) 793–798.<br>591 https://doi.org/10.1093/cid/ciaa345. https://doi.org/10.1093/cid/ciaa345.
- [45] M. Platten, D. Hoffmann, R. Grosser, F. Wisplinghoff, H. Wisplinghoff, G. Wiesmüller, O. Schildgen, V. Schildgen, SARS-CoV-2, CT-Values, and Infectivity—Conclusions to Be Drawn from Side Observations, Viruses. 13 (2021) 1459. https://doi.org/10.3390/v13081459.
- [46] M. Juanola-Falgarona, L. Peñarrubia, S. Jiménez-Guzmán, R. Porco, C. Congost-Teixidor, M. Varo- Velázquez, S.N. Rao, G. Pueyo, D. Manissero, J. Pareja, Ct values as a diagnostic tool for monitoring 597 SARS-CoV-2 viral load using the QIAstat-Dx® Respiratory SARS-CoV-2 Panel, Int. J. Infect. Dis.<br>598 122 (2022) 930–935. https://doi.org/10.1016/j.ijid.2022.07.022. 122 (2022) 930–935. https://doi.org/10.1016/j.ijid.2022.07.022.
- [47] B. Bruijns, L. Folkertsma, R. Tiggelaar, FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances, Biosens. Bioelectron. 11 (2022) 100158. https://doi.org/10.1016/j.biosx.2022.100158.
- [48] G.-S. Park, K. Ku, S.-H. Baek, S.-J. Kim, S.I. Kim, B.-T. Kim, J.-S. Maeng, Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), J. Mol. Diagn. JMD. 22 (2020) 729–735. https://doi.org/10.1016/j.jmoldx.2020.03.006.
- [49] S. Bhadra, T.E. Riedel, S. Lakhotia, N.D. Tran, A.D. Ellington, High-Surety Isothermal Amplification and Detection of SARS-CoV-2, mSphere. 6 (2021) e00911-20. https://doi.org/10.1128/mSphere.00911-20.
- [50] V.L. Dao Thi, K. Herbst, K. Boerner, M. Meurer, L.P. Kremer, D. Kirrmaier, A. Freistaedter, D. Papagiannidis, C. Galmozzi, M.L. Stanifer, S. Boulant, S. Klein, P. Chlanda, D. Khalid, I. Barreto Miranda, P. Schnitzler, H.-G. Kräusslich, M. Knop, S. Anders, A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples, Sci. Transl. Med. 12 (2020) eabc7075. https://doi.org/10.1126/scitranslmed.abc7075.
- [51] J. Qian, S.A. Boswell, C. Chidley, Z. Lu, M.E. Pettit, B.L. Gaudio, J.M. Fajnzylber, R.T. Ingram, R.H. Ward, J.Z. Li, M. Springer, An enhanced isothermal amplification assay for viral detection, Nat. Commun. 11 (2020) 5920. https://doi.org/10.1038/s41467-020-19258-y.
- [52] Y.H. Baek, J. Um, K.J.C. Antigua, J.-H. Park, Y. Kim, S. Oh, Y.-I. Kim, W.-S. Choi, S.G. Kim, J.H. Jeong, B.S. Chin, H.D.G. Nicolas, J.-Y. Ahn, K.S. Shin, Y.K. Choi, J.-S. Park, M.-S. Song, Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-620 detection method for novel SARS-CoV-2, Emerg. Microbes Infect. 9 (2020) 998-1007.<br>621 https://doi.org/10.1080/22221751.2020.1756698. https://doi.org/10.1080/22221751.2020.1756698.
- [53] C. Yan, J. Cui, L. Huang, B. Du, L. Chen, G. Xue, S. Li, W. Zhang, L. Zhao, Y. Sun, H. Yao, N. Li, H. Zhao, Y. Feng, S. Liu, Q. Zhang, D. Liu, J. Yuan, Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay, Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 26 (2020) 773–779. https://doi.org/10.1016/j.cmi.2020.04.001.
- [54] T. Zheng, X. Li, Y. Si, M. Wang, Y. Zhou, Y. Yang, N. Liang, B. Ying, P. Wu, Specific lateral flow detection of isothermal nucleic acid amplicons for accurate point-of-care testing, Biosens. Bioelectron. 222 (2023) 114989. https://doi.org/10.1016/j.bios.2022.114989.
- [55] C. Zhang, J. Lv, Y. Cao, X. Yao, M. Yin, S. Li, J. Zheng, H. Liu, A triple-target reverse transcription loop-mediated isothermal amplification (RT-LAMP) for rapid and accurate detection of SARS-CoV-2 virus, Anal. Chim. Acta. 1255 (2023) 341146. https://doi.org/10.1016/j.aca.2023.341146.
- [56] P. Nuchnoi, P. Piromtong, S. Siribal, K. Anansilp, P. Thichanpiang, P.A. Okada, Applicability of a colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for SARS-CoV-2 detection in high exposure risk setting, Int. J. Infect. Dis. 128 (2023) 285–289. https://doi.org/10.1016/j.ijid.2023.01.010.
- [57] I. Azmi, M.I. Faizan, R. Kumar, S. Raj Yadav, N. Chaudhary, D. Kumar Singh, R. Butola, A. Ganotra, G. Datt Joshi, G. Deep Jhingan, J. Iqbal, M.C. Joshi, T. Ahmad, A Saliva-Based RNA Extraction-

- Free Workflow Integrated With Cas13a for SARS-CoV-2 Detection, Front. Cell. Infect. Microbiol.
- 11 (2021). https://www.frontiersin.org/articles/10.3389/fcimb.2021.632646 (accessed May 30, 2023).
- [58] S. Wei, H. Suryawanshi, A. Djandji, E. Kohl, S. Morgan, E.A. Hod, S. Whittier, K. Roth, R. Yeh, J.C. Alejaldre, E. Fleck, S. Ferrara, D. Hercz, D. Andrews, L. Lee, K.A. Hendershot, J. Goldstein, Y. Suh, M. Mansukhani, Z. Williams, Field-deployable, rapid diagnostic testing of saliva for SARS-CoV-2,
- Sci. Rep. 11 (2021) 5448. https://doi.org/10.1038/s41598-021-84792-8.
- [59] M.A. Lalli, J.S. Langmade, X. Chen, C.C. Fronick, C.S. Sawyer, L.C. Burcea, M.N. Wilkinson, R.S. Fulton, M. Heinz, W.J. Buchser, R.D. Head, R.D. Mitra, J. Milbrandt, Rapid and Extraction-Free 648 Detection of SARS-CoV-2 from Saliva by Colorimetric Reverse-Transcription Loop-Mediated<br>649 Isothermal Amplification, Clin. Chem. 67 (2021) 415–424. Isothermal Amplification, Clin. Chem. 67 (2021) 415–424. https://doi.org/10.1093/clinchem/hvaa267.
- [60] Real-time COVID-19 testing | Cue, (n.d.). https://cuehealth.com/products/how-cue-detects-covid-19/ (accessed September 19, 2023).
- [61] Respiratory Health Test POC rapid PCR device, Visby Med. (n.d.). https://www.visbymedical.com/respiratory-health-test/ (accessed September 19, 2023).
- [62] ID NOW COVID-19 2.0, (n.d.). https://www.globalpointofcare.abbott/us/en/product-details/id-now-covid-19-us.html (accessed September 19, 2023).
- [63] Aptitude, (n.d.). https://www.aptitudemedical.com/product/metrix-covid-19-test (accessed September 19, 2023).
- [64] E.A. Phillips, T.J. Moehling, K.F.K. Ejendal, O.S. Hoilett, K.M. Byers, L.A. Basing, L.A. Jankowski, J.B. Bennett, L.-K. Lin, L.A. Stanciu, J.C. Linnes, Microfluidic rapid and autonomous analytical device (microRAAD) to detect HIV from whole blood samples, Lab. Chip. 19 (2019) 3375–3386. https://doi.org/10.1039/C9LC00506D.
- 

#### **Table 1. Examples of NAATs for SARS-CoV-2 detection**









**Table S2.** LFIA analysis of RT-LAMP performed on 30 clinical samples with and without extraction. IAC and test line intensities of each of 3 replicates of RT-LAMP assays are shown. Intensity of greater than 0.02 or greater is considered positive by eye [64]. P represents positive. N represents negative. Sample ID 6 was the only sample that indicated discordant results between extracted and non-extracted samples.



19					P	0.052	0.041	0.063	0.087	0.094	0.110	0.129	0.115	0.113	0.037	0.079	0.033
20		N	N	N	N	0.100	0.118	0.096	0.000	0.001	0.001	0.082	0.123	0.112	$-0.003$	0.001	0.000
21	$\mathbf{v}$				P	0.099	0.089	0.098	0.019	0.014	0.016	0.120	0.145	0.128	0.033	0.038	0.047
22	$\mathbf{v}$	N	N	N	N	0.075	0.113	0.127	0.000	$-0.001$	0.000	0.137	0.069	0.099	0.001	0.002	0.000
23		N	N	N	N	0.075	0.107	0.121	$-0.001$	$-0.007$	$-0.002$	0.087	0.101	0.096	$-0.001$	0.000	$-0.002$
24		Y	P		P	0.111	0.129	0.111	0.010	0.019	0.013	0.115	0.123	0.112	0.039	0.032	0.026
25		Y	P		P	0.061	0.058	0.063	0.098	0.088	0.075	0.074	0.053	0.081	0.095	0.117	0.110
26	$\mathbf{v}$	Y	P		P	0.081	0.078	0.090	0.078	0.064	0.070	0.131	0.115	0.122	0.062	0.046	0.048
27			P		P	0.079	0.079	0.079	0.124	0.089	0.095	0.085	0.079	0.072	0.081	0.092	0.080
28		N	N	N	N	0.135	0.110	0.115	0.002	0.001	$-0.001$	0.195	0.126	0.152	$-0.004$	$-0.001$	$-0.001$
29	$\mathbf{v}$	N	N	N	N	0.119	0.138	0.117	0.000	$-0.004$	0.000	0.163	0.118	0.143	0.001	0.000	$-0.003$
30		N	N	N	N	0.130	0.100	0.123	$-0.001$	0.000	$-0.001$	0.148	0.141	0.165	$-0.003$	0.004	0.000

**Table S3**. Ct values of clinical sample ID 1-30. A positive result requires a sigmoidal amplification curve in the FAM channel with a Ct value of ≤37, and a sigmoidal amplification curve in the VIC/HEX channel with a Ct value of ≤35. A negative result is indicated by the absence of a sigmoidal amplification curve in the FAM channel with a Ct value of "0" or a sigmoidal amplification curve in the VIC/HEX channel with a Ct value of ≤35. P represents positive. N represents negative.



÷







**Figure S2.** *In-silico* validation of 18S rRNA primer against SARS-CoV-2 genome.



**Figure S3.** Figure S3. Analytical sensitivity 18S rRNA RT-LAMP assay. The amplification plot of 18S rRNA RT-LAMP using various concentration of human RNA control as templates (A). The corresponding gel electrophoresis analysis of 18S rRNA RT-LAMP amplicons (B). The LOD analysis on LFIA (C). The corresponding test band intensity analysis (D).  $n = 3$ ; \*\*\*\* indicates  $p \le 0.0001$ .



**Figure S4.** The usability of 18S rRNA as an IAC in blood sample.  $N = 2$ 





**Figure S5**. Analytical sensitivity of SARS-CoV-2 RT-LAMP assay in saliva with prior heat-treatment. RT-LAMP based detection of inactivated viral particles visualized on (A) gel electrophoresis (B) LFIA, and (C) corresponding test band intensity analysis.  $n = 3$ ; \*\*\*\* indicates  $p \le 0.0001$ .



**Figure S6**. LFIA strips of extracted clinical samples, with the three lines representing "ctrl", "IAC", and test (from the top)

Sample ID 1	Sample ID 2	Sample ID 3	Sample ID 4	Sample ID 5	Sample ID 6	Sample ID <sub>7</sub>	Sample ID 8	Sample ID 9	Sample ID 10
Sample ID 11	Sample ID 12	Sample ID 13	Sample ID 14	Sample ID 15	Sample ID 16	Sample ID 17	Sample ID 18	Sample ID 19	Sample ID 20
Sample ID 21	Sample ID 22	Sample ID 23	Sample ID 24	Sample ID 25	Sample ID 26	Sample ID 27	Sample ID 28	Sample ID 29	Sample ID 30

**Figure S7**. LFIA strips of non-extracted clinical samples